LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Harvard Bioscience Inc

Open

SectorGezondheidszorg

0.44 -2.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.43

Max

0.46

Belangrijke statistieken

By Trading Economics

Inkomsten

48M

-2.3M

Verkoop

-1.3M

20M

Winstmarge

-11.159

Werknemers

330

EBITDA

40M

155K

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+264.58% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.8M

22M

Vorige openingsprijs

2.66

Vorige sluitingsprijs

0.44

Nieuwssentiment

By Acuity

50%

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Harvard Bioscience Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2025, 23:59 UTC

Acquisities, Fusies, Overnames

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sep 2025, 22:02 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Tron Shares Rise After New Investment From Bravemorning

8 sep 2025, 16:14 UTC

Belangrijke Marktbewegers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sep 2025, 16:13 UTC

Belangrijke Marktbewegers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sep 2025, 23:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sep 2025, 22:56 UTC

Marktinformatie

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sep 2025, 22:23 UTC

Marktinformatie

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sep 2025, 21:51 UTC

Marktinformatie

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sep 2025, 21:47 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4B AI Deal With Nebius

8 sep 2025, 21:33 UTC

Acquisities, Fusies, Overnames

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sep 2025, 21:20 UTC

Acquisities, Fusies, Overnames

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sep 2025, 21:19 UTC

Acquisities, Fusies, Overnames

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sep 2025, 21:18 UTC

Acquisities, Fusies, Overnames

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 19:33 UTC

Marktinformatie

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sep 2025, 19:22 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sep 2025, 19:02 UTC

Marktinformatie

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sep 2025, 17:29 UTC

Marktinformatie

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sep 2025, 16:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sep 2025, 16:36 UTC

Marktinformatie

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sep 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 16:16 UTC

Winsten

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 sep 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Harvard Bioscience Inc Prognose

Koersdoel

By TipRanks

264.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1.75 USD  264.58%

Hoogste 3 USD

Laagste 0.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harvard Bioscience Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

0.3 / 0.3401Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

No Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat